Here, we developed novel GEMMs of human B-ALL through transgenic overexpression of Crlf2 and concomitant expression of mutant Jak2 to determine the role of mutant JAK2 in leukemia initiation and maintenance of disease. This evidence concerns the gene CRLF2 and precursor B-cell acute lymphoblastic leukemia.